Research record
Acute myeloid leukemia source map
AML should be handled as its own leukemia track, with attention to marrow findings, cytogenetics, molecular testing, fitness for intensive therapy, transplant discussion, and trials.
What this is
AML should be handled as its own leukemia track, with attention to marrow findings, cytogenetics, molecular testing, fitness for intensive therapy, transplant discussion, and trials.
Why it may come up
- adult AML
- new diagnosis
- relapsed or refractory AML
- trial search
What not to assume
- Do not collapse AML and ALL into one treatment page.
At a glance
Acute myeloid leukemia source map
- Type
- diagnostic-context
- Mutation result
- varies by molecular testing
- Where
- Global
- Evidence status
- Source gives context
- Last checked
- 2026-05-21
What we know
- NCI has a dedicated Adult AML Treatment PDQ patient summary.
What is unclear
- Specific AML mutation records and country access are not built yet.
- Pediatric AML should be sourced separately before public clinical expansion.
Questions to ask
- Is this AML, APL, or another acute leukemia subtype?
- Which cytogenetic or molecular results are pending?
- Is transplant or clinical trial referral being discussed now or later?